• iPSC-Based Prescreening for Ultrarare Disease Clinical Trial

  2026-07-09

  This study presents a personalized induced pluripotent stem cell (iPSC)-based platform to prescreen drug efficacy for patients with ultrarare diseases, addressing the challenge of unpredictable responses in clinical trial enrollment. The approach demonstrates improved safety and efficacy validation, guiding individualized treatment decisions for previously uncharacterized pathogenic mutations.

• CUDC-907: Technical Guide for Dual PI3K and HDAC Inhibition

  2026-07-09

  CUDC-907 provides researchers with a validated tool for simultaneous inhibition of PI3K/AKT and HDAC pathways in established cancer cell models. It is specifically intended for controlled in vitro studies focused on cell signaling, cell cycle arrest, and apoptosis. CUDC-907 should not be used for clinical, diagnostic, or therapeutic applications.

• Surrogate BBB Model with Lysosomal Trapping Correction Advan

  2026-07-08

  The referenced study introduces a high-throughput in vitro blood-brain barrier (BBB) model combining LLC-PK1-MOCK/MDR1 cells and lysosomal trapping correction to predict CNS drug permeability. This approach improves mechanistic resolution and predictive accuracy, streamlining early-stage screening for brain-penetrant therapeutics.

• Reliable Cardiovascular Research with (-)-Norepinephrine (+)

  2026-07-08

  This article addresses key laboratory challenges in adrenergic and cardiomyopathy research, offering scenario-driven guidance for using (-)-Norepinephrine (+)-bitartrate (SKU C8723). By integrating evidence-based protocol parameters and comparative product insights, it empowers biomedical scientists to optimize cell-based and animal model workflows for maximal reproducibility and data integrity.

• Vitamin C (CAS 50-81-7): Mechanism, Benchmarks, and Research

  2026-07-07

  Vitamin C, also known as ascorbic acid, is a water-soluble vitamin with documented anticancer and apoptosis-inducing properties. Recent studies confirm its ability to inhibit tumor cell proliferation and ameliorate cellular senescence via the ROS/NF-κB pathway. APExBIO supplies high-purity Vitamin C (SKU B2064) for research applications requiring reproducibility and validated workflow integration.

• Hydrocortisone as a Glucocorticoid Hormone: Research Workflo

  2026-07-07

  Hydrocortisone is a benchmark glucocorticoid hormone for dissecting rapid signaling and anti-inflammatory pathways across cellular and animal models. From translational neurobiology to advanced inflammation research, this guide details experimental setups, troubleshooting, and data-driven enhancements using APExBIO’s Hydrocortisone B1951.

• FPR2/ALX Stimulation Restricts Autoimmune Astrocytopathy via

  2026-07-06

  This study demonstrates that activating FPR2/ALX with Quin-C1 attenuates neuroinflammation and demyelination in a mouse model of autoimmune astrocytopathy, primarily by modulating microglia and NK cell activity. The findings highlight FPR2/ALX as a promising therapeutic target for disorders such as neuromyelitis optica spectrum disorder (NMOSD), where conventional therapies are often insufficient.

• Lipid Scrambling Modulation Amplifies Ferroptosis and Immune

  2026-07-06

  Yang et al. provide evidence that TMEM16F-mediated lipid scrambling at the plasma membrane suppresses ferroptosis, revealing a mechanism by which tumors evade cell death and immune rejection. Disruption of this process potentiates ferroptosis and synergizes with PD-1 blockade, highlighting new therapeutic angles for cancer treatment.

• 3-Deazaadenosine: Precision Epigenetic Inhibition and Antivi

  2026-07-05

  Explore how 3-Deazaadenosine, a potent S-adenosylhomocysteine hydrolase inhibitor, enables advanced methylation pathway studies and preclinical antiviral research. This article uncovers unique mechanistic insights and protocol strategies for researchers seeking reproducible, high-impact results.

• Prunin Suppresses Senecavirus A by Disrupting IRES-Driven Tr

  2026-07-04

  This study reveals that prunin, a natural compound, inhibits Senecavirus A (SVA) replication by targeting the viral internal ribosome entry site (IRES) and disrupting its interaction with key host RNA-binding proteins. The findings not only illuminate a novel antiviral mechanism against SVA but also provide a strategic foundation for future therapeutic development.

• Ether Lipid Biosynthesis in B Cells Enhances Antibody Respon

  2026-07-03

  This study demonstrates that B cell-intrinsic ether lipid biosynthesis, via the peroxisomal enzyme PexRAP (encoded by Dhrs7b), is crucial for robust germinal center formation and effective antibody affinity maturation. The findings clarify metabolic control points in humoral immunity and suggest new avenues for immunological and translational research.

• Doxorubicin in Translational Oncology: Mechanisms and Strate

  2026-07-03

  This thought-leadership article unpacks the mechanistic underpinnings and strategic application of Doxorubicin (Adriamycin) for translational cancer researchers. Integrating the latest evidence on ABC transporter-mediated resistance and new sensitization strategies, we outline how APExBIO’s Doxorubicin empowers discovery, validation, and workflow innovation across solid tumors and hematologic malignancies.

• ABT-737: Shaping Translational Strategies in Apoptosis Resea

  2026-07-02

  This thought-leadership article explores how ABT-737, a potent BCL-2 protein inhibitor, is redefining translational research by bridging mechanistic insights in apoptosis with actionable guidance for oncology and autoimmune diabetes models. Integrating recent breakthroughs, including senolytic applications and advanced protocol optimization, the piece delivers strategic perspectives for researchers aiming to maximize the impact of apoptosis induction studies.

• Breast Cancer Dependence on MCL-1: Canonical Anti-Apoptotic

  2026-07-02

  This study clarifies that breast cancer cell survival is primarily dependent on the canonical anti-apoptotic function of MCL-1, rather than its non-apoptotic roles. These findings underline the therapeutic potential of MCL-1 inhibitors and inform the design of targeted apoptosis induction assays in cancer research.

• MK-2206 Dihydrochloride: Advanced Workflows in Akt Pathway R

  2026-07-01

  MK-2206 dihydrochloride empowers researchers to dissect PI3K/Akt/mTOR signaling with nanomolar precision, streamlining apoptosis and metabolic studies in cancer and bone biology. This guide delivers actionable workflow optimizations, troubleshooting strategies, and cross-domain insights tied to the latest discoveries in Wnt-driven osteogenesis.

11932 records 5/796 page Previous Next 12345 下5页 Last page